NANJING, China, Sept. 22, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company", Stock Code: 9887.HK) announced that the U.S. Food and Drug Administration (FDA) has approved its first-in-human Investigational New Drug (IND) application for LBL-047 on...
Hence then, the article about first in class potential fda clears ind application for lbl 047 an anti bdca2 taci bispecific fusion protein developed by leads biolabs was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( First-in-Class Potential! FDA Clears IND Application for LBL-047, an Anti-BDCA2/TACI Bispecific Fusion Protein Developed by Leads Biolabs )
Also on site :
- Neon Counters A24’s SCP Foundation Movie With “Open-Source” Project To Release Under Creative Commons License
- Box Office: ‘Verity’ Aims for $35 Million Debut and Anne Hathaway’s Third No. 1 Movie of the Year, ‘Digger’ Could Bomb With $12 Million
- In 1983, Congress set aside $42 million to move a Pennsylvania town off a burning coal seam; Centralia went from 1,017 residents to five by 2020